|
1
|
Roseman S: Reflections on glycobiology. J
Biol Chem. 276:41527–41542. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu YC, Yen HY, Chen CY, et al:
Sialylation and fucosylation of epidermal growth factor receptor
suppress its dimerization and activation in lung cancer cells. Proc
Natl Acad Sci USA. 108:11332–11337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Javaud C, Dupuy F, Maftah A, et al: The
fucosyltransferase gene family: an amazing summary of the
underlying mechanisms of gene evolution. Genetica. 118:157–170.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matzhold EM, Helmberg W, Wagner T, et al:
Identification of 14 new alleles at the fucosyltransferase 1, 2,
and 3 loci in Styrian blood donors, Austria. Transfusion.
49:2097–2108. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dettke M, Pálfi G and Loibner H:
Activation-dependent expression of the blood group-related Lewis Y
antigen on peripheral blood granulocytes. J Leukoc Biol.
68:511–514. 2000.PubMed/NCBI
|
|
6
|
Hokke CH, Neeleman AP, Koeleman CA and van
den Eijinden DH: Identification of an α3-fucosyltransferase and a
novel α2-fucosyltransferase activity in cercariae of the
schistosome Trichobilharzia ocellata: biosynthesis of the
Fucα1-->2Fucα1-->3[Gal(NAc)β1-->4] GlcNAc sequence.
Glycobiology. 8:393–406. 1998.
|
|
7
|
Nakagoe T, Fukushima K, Itoyanagi N, et
al: Expression of ABH/Lewis-related antigens as prognostic factors
in patients with breast cancer. J Cancer Res Clin Oncol.
128:257–264. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsuboi K, Asao T, Ide M, et al:
α1,2-fucosylation is a superior predictor of postoperative
prognosis for colorectal cancer compared with blood group A, B, or
sialyl Lewis X antigen generated within colorectal tumor tissue.
Ann Surg Oncol. 14:1880–1889. 2007.
|
|
9
|
Madjd Z, Parsons T, Watson NF, Spendlove
I, Ellis I and Durrant LG: High expression of Lewis y/b antigens is
associated with decreased survival in lymph node negative breast
carcinomas. Breast Cancer Res. 7:R780–787. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arai Y and Nishida M: Differential
diagnosis between normal endometrium and endometrial hyperplasia
with immunostaining cytology using anti-LeY monoclonal antibody.
Int J Gynecol Cancer. 13:42–46. 2003. View Article : Google Scholar
|
|
11
|
Kim YS, Yuan M, Itzkowitz SH, et al:
Expression of LeY and extended LeY blood group-related antigens in
human malignant, premalignant, and non-malignant colonic tissues.
Cancer Res. 46:5985–5992. 1986.PubMed/NCBI
|
|
12
|
Kitamura K, Stockert E, Garin-Chesa P, et
al: Specificity analysis of blood group Lewis-y (Le(y)) antibodies
generated against synthetic and natural Le(y) determinants. Proc
Natl Acad Sci USA. 91:12957–12961. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iwamori M, Tanaka K, Kubushiro K, et al:
Alterations in the glycolipid composition and cellular properties
of ovarian carcinoma-derived RMG-1 cells on transfection of the α1,
2-fucosyltransferase gene. Cancer Sci. 96:26–30. 2005.PubMed/NCBI
|
|
14
|
Zhao Y, Lin B, Hao YY, et al: The effects
of Lewis (y) antigen content on drug resistance to carboplatin in
ovarian cancer line RMG-I. Prog Biochem Biophys. 35:1175–1182.
2008.
|
|
15
|
Liu JJ, Lin B, Hao YY, et al: Lewis(y)
antigen stimulates the growth of ovarian cancer cells via
regulation of the epidermal growth factor receptor pathway. Oncol
Rep. 23:833–841. 2010.PubMed/NCBI
|
|
16
|
Brennan PJ, Kumogai T, Berezov A, et al:
HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene.
19:6093–6101. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Slamon DJ, Godolphin W and Jones LA:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gravalos C and Jimeno A: HER2 in Gastric
Cancer: A New Prognostic Factor and a Novel Therapeutic Target. Ann
Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Owens MA, Horten BC and Da Silva MM: HER2
amplification ratios by fluorescence in situ hybridization and
correlation with immunohistochemistry in a cohort of 6556 breast
cancer tissues. Clin Breast Cancer. 5:63–69. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Palumberi D, Aldi S, Ermini L, et al:
RNA-mediated gene silencing of FUT1 and FUT2 influences
expression and activities of bovine and human fucosylated nucleolin
and inhibits cell adhesion and proliferation. J Cell Biochem.
111:229–238. 2010.PubMed/NCBI
|
|
21
|
Chang WW, Lee CH, Lee P, et al: Expression
of Globo H and SSEA3 in breast cancer stem cells and the
involvement of fucosyl transferases 1 and 2 in Globo H synthesis.
Proc Natl Acad Sci USA. 105:11667–11672. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mittendorf EA, Liu Y, Tucker SL, et al: A
novel interaction between HER2/neu and cyclin E in breast cancer.
Oncogene. 29:3896–3907. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tanner M, Hollmén M, Junttila TT, et al:
Amplification of HER-2 in gastric carcinoma: association with
Topoisomerase IIa gene amplification, intestinal type, poor
prognosis and sensitivity to trastuzumab. Ann Oncol. 16:273–278.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brockhoff G, Heckel B, Schmidt-Bruecken E,
et al: Differential impact of Cetuximab, Pertuzumab and Trastuzumab
on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif.
40:488–507. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Patel D, Bassi R, Hooper A, et al:
Anti-epidermal growth factor receptor monoclonal antibody cetuximab
inhibits EGFR/HER-2 heterodimerization and activation. Cancer Sci.
99:1611–1617. 2008.PubMed/NCBI
|
|
26
|
Zhang Z, Sun P, Liu J, et al: Suppression
of FUT1/FUT4 expression by siRNA inhibits tumor growth.
Biochim Biophys Acta. 1783:287–296. 2008.
|
|
27
|
Miyoshi E, Moriwaki K and Nakagawa T:
Biological function of fucosylation in cancer biology. J Biochem.
143:725–729. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Gu J, Ihara H, et al: Core
fucosylation regulates epidermal growth factor receptor-mediated
intracellular signaling. J Biol Chem. 281:2572–2577. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dogan I, Cumaoglu A, Aricioglu A and
Ekmekci A: Inhibition of ErbB2 by herceptin reduces viability and
survival, induces apoptosis and oxidative stress in Calu-3 cell
line. Mol Cell Biochem. 347:41–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bijman MN, van Berkel MP, Kok M, Janmaat
ML and Boven E: Inhibition of functional HER family members
increases the sensitivity to docetaxel in human ovarian cancer cell
lines. Anticancer Drugs. 20:450–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kruser TJ and Wheeler DL: Mechanisms of
resistance to HER family targeting antibodies. Exp Cell Res.
316:1083–1100. 2010. View Article : Google Scholar : PubMed/NCBI
|
